Stock CNTA CENTESSA PHARMACEUTICALS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Centessa Pharmaceuticals plc

Equities

CNTA

US1523091007

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-05 pm EDT 		5-day change 1st Jan Change
8.8 USD +4.14% Intraday chart for Centessa Pharmaceuticals plc +9.45% +10.55%
May. 31 Nxera Pharma to Receive $4.6 Million Milestone Payments From Centessa Pharmaceuticals MT
May. 13 Centessa Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
AQ
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
GL
Centessa Pharmaceuticals : 2023 UK Annual Report and Accounts
PU
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
GL
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
GL
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
GL
Centessa Pharmaceuticals Announces Open IND for ORX750, Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
AQ
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
GL
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
AQ
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
GL
Centessa Pharmaceuticals : March Corporate Overview
PU
Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference
GL
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
GL
Scion Life Sciences Launches with Oversubscribed $310 Million Fund to Create and Build Exceptional Biotech Companies
AQ
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
GL
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
AQ
Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference
GL
Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia
AQ
Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia
AQ
Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CNTA Stock
  4. News Centessa Pharmaceuticals plc
  5. Press Releases